Literature DB >> 25332532

Autoimmune haemolytic anaemia emerging during Campath treatment in a patient with CD5 negative chronic lymphocytic leukaemia.

Paul R J Ames1, Darren Aw2, Mervin G Rainey2.   

Abstract

Campath is being employed for the treatment of autoimmune haemolytic anemia (AIHA) whether or not associated to B cell chronic lymphoid leukaemia (CLL). CD5 negative CLL is relatively uncommon and runs an indolent course. We report a CD5 negative CLL patient who developed AIHA associated with cytomegalovirus infection reactivation whilst on treatment with Campath for progressive disease.

Entities:  

Keywords:  CMV; Campath; Haemolytic anemia; Lymphoid leukaemia

Year:  2013        PMID： 25332532      PMCID： PMC4192225          DOI： 10.1007/s12288-013-0239-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  18 in total

1.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia.

Authors:  C H Geisler; J K Larsen; N E Hansen; M M Hansen; B E Christensen; B Lund; H Nielsen; T Plesner; K Thorling; E Andersen
Journal:  Blood       Date:  1991-10-01       Impact factor: 22.113

3.  Cytomegalovirus reactivation exacerbated thrombocytopenia and haemolysis in a patient with systemic lupus erythematosus.

Authors:  Toshiro Sugimoto; Masahiro Aoyama; Naoko Takeda; Masayoshi Sakaguchi; Yoshihiko Nishio; Takashi Uzu; Atsunori Kashiwagi
Journal:  Rheumatol Int       Date:  2007-06-13       Impact factor: 2.631

4.  CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 cases.

Authors:  G Cartron; C Linassier; J L Bremond; B Desablens; M T Georget; B Fimbel; F Luthier; J L Dutel; J P Lamagnere; P Colombat
Journal:  Leuk Lymphoma       Date:  1998-09

Review 5.  Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment.

Authors:  Melca M O Barros; Morris A Blajchman; José O Bordin
Journal:  Transfus Med Rev       Date:  2010-07

6.  The effect of treatment with Campath-1H in patients with autoimmune cytopenias.

Authors:  F Willis; J C Marsh; D H Bevan; S B Killick; G Lucas; R Griffiths; W Ouwehand; G Hale; H Waldmann; E C Gordon-Smith
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

7.  Hemolytic anemia due to acute cytomegalovirus infection in an immunocompetent adult: a case report and review of the literature.

Authors:  Fabrizio Taglietti; Cecilia M Drapeau; Elisabetta Grilli; Alessandro Capone; Pasquale Noto; Simone Topino; Nicola Petrosillo
Journal:  J Med Case Rep       Date:  2010-10-21

8.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

Authors:  M Q Xia; G Hale; M R Lifely; M A Ferguson; D Campbell; L Packman; H Waldmann
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

9.  Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.

Authors:  Philippe Rodon; Philippe Breton; Gery Courouble
Journal:  Eur J Haematol       Date:  2003-05       Impact factor: 2.997

10.  CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients.

Authors:  C Soderberg; S Sumitran-Karuppan; P Ljungman; E Moller
Journal:  Transplantation       Date:  1996-02-27       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.